Figure S2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
<p>Treatment with IPH5201 3,000 mg saturates both soluble CD39 in sera and membrane-bound CD39 on immune cells.</p>
Authors
- Meredith McKean (ORCID: https://orcid.org/0000-0003-0944-7418)
- Vicky Barnhart
- Eric Tu
- Raymond Mager (ORCID: https://orcid.org/0009-0004-6753-7416)
- Martina Imbimbo (ORCID: https://orcid.org/0000-0003-2521-7540)
- Chunling Fan (ORCID: https://orcid.org/0009-0001-9259-7064)
- Carine Paturel
- Yun He (ORCID: https://orcid.org/0000-0002-0077-3113)
- Steven Eck (ORCID: https://orcid.org/0000-0001-6074-8430)
- Paula G. Fraenkel (ORCID: https://orcid.org/0000-0001-8894-0117)
- Antoîne Italiano (ORCID: https://orcid.org/0000-0002-8540-5351)
- Elina Murtomaki
- Benedito A. Carneiro (ORCID: https://orcid.org/0000-0002-5468-1126)
- Zachary A. Cooper (ORCID: https://orcid.org/0000-0003-1059-0940)
- Patricia Martín-Romano (ORCID: https://orcid.org/0000-0002-3923-5160)
- Teresa Macarulla (ORCID: https://orcid.org/0000-0002-5856-4082)
- Antoine Hollebecque (ORCID: https://orcid.org/0000-0003-2869-7551)
- John D. Powderly (ORCID: https://orcid.org/0000-0002-7608-0380)
- Arsène‐Bienvenu Loembé (ORCID: https://orcid.org/0009-0001-2557-8170)
- Eduardo Castañón Álvarez (ORCID: https://orcid.org/0000-0003-2957-4414)
- Agnes Boyer Chamard
Publication Details
- Published
- 2025-09-22
- DOI
- https://doi.org/10.1158/2767-9764.30177718
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00